Back to Screener

Healthcare

Dechra Pharmaceuticals PLC(DCHPF)

Live Price

Offline

$46.90

-0.21% today

1Y Change

Window

No data

Market Cap
$5.34B
Revenue Growth
+11.7%
EPS Growth
-144.4%
Dividend Yield
0.3%
No coverage

Historical coverage is still loading

We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.

No price data

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Dechra Pharmaceuticals PLC (DCHPF) is a Healthcare stock with a market cap of $5.34B. The stock last traded around $46.90. Baseline metrics include revenue growth of +11.7%, EPS growth of -144.4%, a dividend yield of 0.3%. What stands out right now is revenue +11.7%, EPS -144.4%, free cash flow -26.5% with operating margin 0.8% and ROIC 0.3%. The dividend is present but secondary, with a yield around 0.3%. Valuation sits in the middle of the pack at price/sales 5.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DCHPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+11.7% vs +7.6% peer median

Operating Margin

Below sector median

+0.8% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

The operating picture looks softer than before

Revenue is at +11.7% and EPS is at -144.4%, with operating margin around 0.8%.

Shareholder return is still part of the story

The stock is still offering a dividend yield around 0.3%, which matters if the thesis depends on income as much as growth.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

DCHPF

Normalized return

SPY

S&P 500

Excess Return

Relative to SPY

DCHPF Max Drawdown

Trailing 1Y

SPY Max Drawdown

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for DCHPF and SPY.

Calendar-year return history is still loading or unavailable.
DE

Company Overview

Dechra Pharmaceuticals PLC

Last Updated
May 15, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
EV/EBITDA
55.8
Price/Sales
5.8
Price/Book
5.8

Growth

Revenue
+11.7%
EPS
-144.4%
Free Cash Flow
-26.5%

Profitability

Gross Margin
56.0%
Operating Margin
0.8%
Net Margin
-3.7%
ROE
-3.9%
ROIC
0.3%

Balance Sheet

Debt/Equity
0.67
Current Ratio
2.85

Earnings Reports

No earnings data available

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.